🔗 Share this article

An underground economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Investigational Drug Acquiring Traction Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Viewers are urged to message these accounts privately for supplier links, while also obtaining promotional offers.

Thriving Trade on Messaging Platforms

Additionally, a flourishing market exists on Telegram, where groups with thousands of members share “before and after” images, administration instructions and claims of next-day British shipping. Sellers promote the drug there before directing buyers to WhatsApp for purchases.

Understanding Retatrutide

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Medical Professionals Express Concerns

However, doctors and pharmacists have cautions that the distribution of what is still an unapproved drug in the UK is a cause for concern and could lead to users injecting products of uncertain source.

Several professionals stated the popularity for the experimental drug could be connected to the rising cost of licensed slimming products such as Mounjaro.

Legal Position and Enforcement

Selling the unapproved drug on TikTok or messaging apps is illegal in the United Kingdom, as it is an unapproved drug that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to circumvent the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and supply can still violate medicines, marketing, and customer laws, potentially leading to fines, legal action or imprisonment.

Platform Response and Content Removal

According to the social media company, the platform has removed problematic material and prohibited related hashtags and search suggestions. The organization stated it was committed to maintaining the platform safe and investing in strengthening compliance measures.

Online Marketplace Activities

Investigations also found groups with up to nine thousand members selling retatrutide using the platform's built-in search feature, which operates like a online catalog. Typing “retatrutide” immediately displays groups with thousands of users, populated with images of weight loss, glowing reviews and detailed guides for mixing or administering at home.

Within moments of joining one group, a vendor posted contact information, where the majority of transactions occur. The seller provided an guidebook and guaranteed delivery within two days. When asked whether the substance was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about weight, health issues or previous experience.

Item Details and Pricing

Inside these groups, messages display dark colored packages with postal service stickers, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at home with purified liquid, or ready-to-use pens usually sold at 160 pounds for 20 milligrams. When asked how much time a pen should last, vendors give contradictory responses ranging from a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A representative for the messaging service stated it actively monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are administering materials they cannot confirm. Although the science behind retatrutide is sound, these digital products may not contain what they claim,” said Jason Murphy, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to recent cost increases for approved slimming drugs such as Mounjaro. “With costs increasing, individuals are using social media. But fake treatments are extremely dangerous. You cannot know what’s contained or whether the environment they were made in was sterile,” she said.

Her staff has previously seen patients injured by personal administration from unconfirmed sources. “We recognize the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” said the doctor. “These substances could be impure or improperly measured.”

Producer Statement

A representative from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they said, noting that any item “misleadingly claiming itself as a Lilly investigational product not yet approved … may subject patients to potentially serious medical dangers”.